Brief: Regeneron Provides Update On Phase 3 Trial Of Fianlimab (Lag-3 Inhibitor) Combination In First-Line Unresectable Or Metastatic Melanoma
16/05/2026 01:24
May 16 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: REGENERON PROVIDES UPDATE ON PHASE 3 TRIAL OF FIANLIMAB (LAG-3 INHIBITOR) COMBINATION IN FIRST-LINE UNRESECTABLE OR METASTATIC MELANOMA REGENERON PHARMACEUTICALS: TRIAL DID NOT REACH STATISTICAL SIGNIFICANCE FOR PRIMARY ENDPOINT OF IMPROVEMENT IN PROGRESSION-FREE SURVIVAL (PFS) Source text: ID:nGNX999tvN Further company coverage: REGN.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement